Administration through the nasal mucosa. Some peptides (Semax, Selank, oxytocin) are administered intranasally to bypass GI degradation and potentially access the blood-brain barrier more directly.
"Intranasal" is filed under Administration in the PeptideAtlas glossary, alongside 15 other terms in that group.
The term applies directly to 9 compound profiles here: PT-141 (evidence A), Selank (evidence D), Semax (evidence D), Oxytocin (evidence A), Desmopressin (evidence A), Nafarelin (evidence A), Buserelin (evidence A), IM862 (evidence D), and others. Each profile states the strength of the human evidence rather than only what the compound is claimed to do.
1 other glossary entry refer to this term in their own definition, which is usually the fastest way to see how it is used in practice.
A selective permeability barrier formed by tightly joined endothelial cells lining brain capillaries. Prevents most peptides from reaching brain tissue. Intranasal delivery, lipophilic modifications, or small peptide size can help bypass the BBB.
An injection administered into the fatty tissue layer between the skin and muscle. The most common route for peptide self-administration.
An injection administered directly into a muscle. Some peptides may be administered via IM injection under medical supervision.
Administration directly into a vein. Provides 100% bioavailability but requires medical supervision and sterile technique.
Compounds where this applies: PT-141, Selank, Semax, Oxytocin, Desmopressin, Nafarelin, Buserelin, IM862, Glucagon.
Terms that reference this one: Blood-Brain Barrier (BBB).
More Administration terms: Subcutaneous (SubQ), Intramuscular (IM), Intravenous (IV), Sublingual, Topical Peptide, Transdermal, Microneedle Patch, Insulin Syringe, Titration, Loading Dose, Maintenance Dose, Peptide Stack, Lipohypertrophy, Injection Site Rotation, Intranasal Delivery.